CG Oncology Inc
CGON40.064USD
-0.156-0.39%
交易中 （美东）报价延迟15分钟
3.05B总市值
亏损市盈率 TTM
关于 CG Oncology Inc 公司
CG Oncology, Inc. 是一家后期临床生物制药公司，专注于开发和商业化一种潜在的膀胱保留疗法，用于治疗患有膀胱癌的患者。该公司的候选产品 cretostimogene 最初处于临床开发阶段，用于治疗非肌层浸润性膀胱癌 (NMIBC) 患者。其主要候选药物 BOND-003 是一种靶向溶瘤膀胱内给药免疫治疗药物，目前处于 II 期，用于治疗对卡介苗 (BCG) 无反应和中等风险的 NMIBC 疾病。其另一款候选产品 CORE-001 是一项 II 期单组开放标签临床试验，研究 cretostimogene 对 BCG 无反应的 NMIBC 患者的疗效。该公司的产品组合还包括 PIVOT-006，这是一项 III 期试验，旨在评估辅助性 cretostimogene 作为单一疗法对经尿道膀胱肿瘤切除术 (TURBT) 后的中危 NMIBC 患者使用的安全性和有效性。
CG Oncology Inc简介
公司代码CGON
公司名称CG Oncology Inc
上市日期Jan 25, 2024
CEOMr. Arthur Kuan
员工数量113
证券类型Ordinary Share
年结日Jan 25
公司地址400 Spectrum Center Drive
城市IRVINE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92618
电话19492886298
网址https://www.cgoncology.com/
公司代码CGON
上市日期Jan 25, 2024
CEOMr. Arthur Kuan
CG Oncology Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Hong Fang (Simone) Song
Ms. Hong Fang (Simone) Song
Independent Director
Independent Director
350.77K
-42.86%
Mr. Arthur Kuan
Mr. Arthur Kuan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
36.15K
--
Dr. Brian Liu, M.D.
Dr. Brian Liu, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua F. Patterson
Mr. Joshua F. Patterson
Chief Compliance Officer, General Counsel and Secretary
Chief Compliance Officer, General Counsel and Secretary
--
--
Dr. James J. Mule, Ph.D.
Dr. James J. Mule, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ambaw Bellete
Mr. Ambaw Bellete
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Susan Graf
Ms. Susan Graf
Independent Director
Independent Director
--
--
Dr. Leonard Post, Ph.D.
Dr. Leonard Post, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Vijay Kasturi, M.D.
Dr. Vijay Kasturi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Victor Tong, Jr.
Mr. Victor Tong, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Hong Fang (Simone) Song
Ms. Hong Fang (Simone) Song
Independent Director
Independent Director
350.77K
-42.86%
Mr. Arthur Kuan
Mr. Arthur Kuan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
36.15K
--
Dr. Brian Liu, M.D.
Dr. Brian Liu, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua F. Patterson
Mr. Joshua F. Patterson
Chief Compliance Officer, General Counsel and Secretary
Chief Compliance Officer, General Counsel and Secretary
--
--
Dr. James J. Mule, Ph.D.
Dr. James J. Mule, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ambaw Bellete
Mr. Ambaw Bellete
President, Chief Operating Officer
President, Chief Operating Officer
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 9月20日 周六
更新时间: 9月20日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.61%
Decheng Capital LLC
8.36%
Longitude Capital Management Co., LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.01%
Fidelity Management & Research Company LLC
4.88%
其他
67.03%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.61%
Decheng Capital LLC
8.36%
Longitude Capital Management Co., LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.01%
Fidelity Management & Research Company LLC
4.88%
其他
67.03%
股东类型
持股股东
占比
Investment Advisor
38.21%
Investment Advisor/Hedge Fund
24.29%
Hedge Fund
19.23%
Venture Capital
19.17%
Private Equity
7.70%
Research Firm
5.20%
Corporation
1.99%
Individual Investor
1.17%
Bank and Trust
0.62%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
328
87.62M
114.91%
-806.86K
2025Q2
290
81.67M
107.14%
+90.58K
2025Q1
288
86.81M
115.41%
+1.61M
2024Q4
256
82.05M
109.64%
+13.55M
2024Q3
219
66.16M
97.22%
+6.06M
2024Q2
188
57.85M
87.34%
+13.21M
2024Q1
138
53.32M
80.66%
+29.28M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
5.90M
7.73%
+70.19K
+1.20%
Jun 30, 2025
Decheng Capital LLC
6.37M
8.36%
--
--
Jun 30, 2025
Longitude Capital Management Co., LLC
4.66M
6.11%
--
--
Sep 11, 2025
BlackRock Institutional Trust Company, N.A.
3.82M
5.01%
-41.95K
-1.09%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.72M
4.88%
+1.30M
+53.90%
Jun 30, 2025
TCG Crossover Management, LLC
3.67M
4.81%
--
--
Jun 30, 2025
ORI Capital Limited
3.58M
4.7%
-10.40K
-0.29%
Apr 08, 2025
Braidwell LP
3.28M
4.31%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
3.23M
4.23%
+145.00K
+4.71%
Jun 30, 2025
Kynam Capital Management LP
2.46M
3.22%
-154.00K
-5.90%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ALPS Medical Breakthroughs ETF
1.87%
Tema Oncology ETF
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
1.1%
Global X Aging Population ETF
0.68%
SPDR S&P Biotech ETF
0.64%
Goldman Sachs Future Health Care Equity ETF
0.52%
First Trust Small Cap Growth AlphaDEX Fund
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.33%
ProShares Ultra Nasdaq Biotechnology
0.32%
Invesco Nasdaq Biotechnology ETF
0.31%
查看更多
ALPS Medical Breakthroughs ETF
占比1.87%
Tema Oncology ETF
占比1.53%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.1%
Global X Aging Population ETF
占比0.68%
SPDR S&P Biotech ETF
占比0.64%
Goldman Sachs Future Health Care Equity ETF
占比0.52%
First Trust Small Cap Growth AlphaDEX Fund
占比0.34%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.33%
ProShares Ultra Nasdaq Biotechnology
占比0.32%
Invesco Nasdaq Biotechnology ETF
占比0.31%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
